Cymabay Therapeutics (CBAY) 5.00 $CBAY
CymaBay product candidate an Orphan Drug for severe hypertriglyceridemia
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 8:34AM CDT
CBAY: 5.00 (-0.14)
CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Severe Hypertriglyceridemia
Marketwired - Wed Apr 22, 7:02AM CDT
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for MBX-8025 to treat patients with hyperlipoproteinemia types I or V (Fredrickson classification). MBX-8025 is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist being evaluated by CymaBay in high unmet need and orphan diseases. Recently, the FDA also granted orphan drug designation for MBX-8025 to treat patients with homozygous familial hypercholesterolemia (HoFH).
CBAY: 5.00 (-0.14)
CymaBay Therapeutics Strengthens Management Team With the Appointment of Kirk Rosemark to VP, Regulatory Affairs and Quality Assurance
Marketwired - Mon Apr 20, 7:02AM CDT
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, today announced the appointment of Kirk Rosemark to Vice President of Regulatory Affairs and Quality Assurance, effective April 27, 2015. Mr. Rosemark will report directly to Harold Van Wart, CymaBay's Chief Executive Officer.
CBAY: 5.00 (-0.14)
CymaBay to Present at the 14th Annual Needham Healthcare Conference
Marketwired - Tue Apr 07, 6:00AM CDT
CymaBay Therapeutics Inc. (NASDAQ: CBAY) announced today that Harold Van Wart, Ph.D., President and Chief Executive Officer, will present a corporate update at the 14th Annual Needham Healthcare Conference on Tuesday, April 14, at 12:10 p.m. ET at the Westin Grand Central Hotel in New York City.
CBAY: 5.00 (-0.14)
CymaBay's MBX-8025 an Orphan Drug for genetic hypercholesterolemia
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 9:00AM CDT
CBAY: 5.00 (-0.14)
CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Homozygous Familial Hypercholesterolemia
Marketwired - Wed Mar 25, 7:02AM CDT
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for MBX-8025 as a treatment for homozygous familial hypercholesterolemia (HoFH). MBX-8025 is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist being evaluated in high unmet need and orphan diseases.
CBAY: 5.00 (-0.14)
CymaBay Therapeutics Appoints Robert J. Wills, Ph.D. to Board of Directors
Marketwired - Tue Mar 24, 7:02AM CDT
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced the appointment of Robert J. Wills, Ph.D., to the Company's Board of Directors.
CBAY: 5.00 (-0.14)
CymaBay Therapeutics to Host Key Opinion Leader Meeting on March 27 in New York City
Marketwired - Mon Mar 23, 9:01AM CDT
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced that it will host a Key Opinion Leader breakfast focused on gout, current treatment options and the company's Phase 2 drug candidate arhalofenate. The event and live webcast will take place on Friday, March 27 from 8:00 am-9:30 am Eastern Time in New York City.
CBAY: 5.00 (-0.14)
CymaBay Therapeutics' (CBAY) CEO Harold Van Wart on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Mar 18, 9:34PM CDT
CBAY: 5.00 (-0.14)
CymaBay Therapeutics EPS of -$0.87
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 3:21PM CDT
CBAY: 5.00 (-0.14)
CymaBay Reports Fourth Quarter and Full Year 2014 Financial Results
Marketwired - Wed Mar 18, 3:01PM CDT
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders, today provided recent corporate highlights and announced financial results for the quarter and year ended December 31, 2014.
CBAY: 5.00 (-0.14)
CymaBay Therapeutics to Announce Fourth Quarter and Year-End 2014 Financial Results and Business Update on Wednesday, March 18, 2015
Marketwired - Wed Mar 11, 7:02AM CDT
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that it will host a conference call and live audio webcast on Wednesday, March 18 at 4:15 p.m. Eastern Time (1:15 p.m. Pacific Time) to discuss the Company's financial results for the quarter and year ended December 31, 2014 and to provide a general business update.
CBAY: 5.00 (-0.14)
CymaBay product candidate an Orphan Drug for severe hypertriglyceridemia
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 8:34AM CDT
CBAY: 5.00 (-0.14)
CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Severe Hypertriglyceridemia
Marketwired - Wed Apr 22, 7:02AM CDT
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for MBX-8025 to treat patients with hyperlipoproteinemia types I or V (Fredrickson classification). MBX-8025 is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist being evaluated by CymaBay in high unmet need and orphan diseases. Recently, the FDA also granted orphan drug designation for MBX-8025 to treat patients with homozygous familial hypercholesterolemia (HoFH).
CBAY: 5.00 (-0.14)
CymaBay Therapeutics Strengthens Management Team With the Appointment of Kirk Rosemark to VP, Regulatory Affairs and Quality Assurance
Marketwired - Mon Apr 20, 7:02AM CDT
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, today announced the appointment of Kirk Rosemark to Vice President of Regulatory Affairs and Quality Assurance, effective April 27, 2015. Mr. Rosemark will report directly to Harold Van Wart, CymaBay's Chief Executive Officer.
CBAY: 5.00 (-0.14)
CymaBay to Present at the 14th Annual Needham Healthcare Conference
Marketwired - Tue Apr 07, 6:00AM CDT
CymaBay Therapeutics Inc. (NASDAQ: CBAY) announced today that Harold Van Wart, Ph.D., President and Chief Executive Officer, will present a corporate update at the 14th Annual Needham Healthcare Conference on Tuesday, April 14, at 12:10 p.m. ET at the Westin Grand Central Hotel in New York City.
CBAY: 5.00 (-0.14)
CymaBay's MBX-8025 an Orphan Drug for genetic hypercholesterolemia
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 9:00AM CDT
CBAY: 5.00 (-0.14)
CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Homozygous Familial Hypercholesterolemia
Marketwired - Wed Mar 25, 7:02AM CDT
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for MBX-8025 as a treatment for homozygous familial hypercholesterolemia (HoFH). MBX-8025 is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist being evaluated in high unmet need and orphan diseases.
CBAY: 5.00 (-0.14)
CymaBay Therapeutics Appoints Robert J. Wills, Ph.D. to Board of Directors
Marketwired - Tue Mar 24, 7:02AM CDT
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced the appointment of Robert J. Wills, Ph.D., to the Company's Board of Directors.
CBAY: 5.00 (-0.14)
CymaBay Therapeutics to Host Key Opinion Leader Meeting on March 27 in New York City
Marketwired - Mon Mar 23, 9:01AM CDT
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced that it will host a Key Opinion Leader breakfast focused on gout, current treatment options and the company's Phase 2 drug candidate arhalofenate. The event and live webcast will take place on Friday, March 27 from 8:00 am-9:30 am Eastern Time in New York City.
CBAY: 5.00 (-0.14)
CymaBay Therapeutics' (CBAY) CEO Harold Van Wart on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Mar 18, 9:34PM CDT
CBAY: 5.00 (-0.14)
CymaBay Therapeutics EPS of -$0.87
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 3:21PM CDT
CBAY: 5.00 (-0.14)
CymaBay Reports Fourth Quarter and Full Year 2014 Financial Results
Marketwired - Wed Mar 18, 3:01PM CDT
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders, today provided recent corporate highlights and announced financial results for the quarter and year ended December 31, 2014.
CBAY: 5.00 (-0.14)
CymaBay Therapeutics to Announce Fourth Quarter and Year-End 2014 Financial Results and Business Update on Wednesday, March 18, 2015
Marketwired - Wed Mar 11, 7:02AM CDT
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that it will host a conference call and live audio webcast on Wednesday, March 18 at 4:15 p.m. Eastern Time (1:15 p.m. Pacific Time) to discuss the Company's financial results for the quarter and year ended December 31, 2014 and to provide a general business update.
CBAY: 5.00 (-0.14)
